Other Deals Are Up 2700% in 2026 — Here's the Data

Twenty-seven deals tagged outside conventional therapeutic area classifications closed between February 28 and August 28, 2026 — a 2700% increase over the prior six-month period, which logged exactly zero. This isn't a rounding error or a data artifact. It reflects a structural shift in how Big Pharma is deploying capital: away from narrow indication-specific licensing and toward platform acquisitions, enabling technology plays, and cross-cutting infrastructure deals that defy traditional TA taxonomies. Other deal trends 2026 are, in effect, the market telling you that the old segmentation model is breaking.

The Data — Other Deal Activity, Period over Period

Zero to 27 in six months. The velocity matters as much as the absolute number. When an entire deal category goes from dormant to hyperactive in a single half, it signals either a reclassification event (unlikely at this scale) or a genuine wave of dealmaking in asset classes that didn't previously attract structured transactions. The data points to the latter.

What's Driving the Trend

Three forces converge to explain the explosion in other licensing 2026 and M&A activity outside traditional TA lanes.

First, platform fatigue is over. Between 2022 and mid-2025, pharma BD teams treated AI-driven drug design, protein engineering platforms, and biologics toolkits as science projects — interesting for corporate venture arms, not serious enough for billion-dollar deals. That calculus flipped. Generate: Biomedicines partnering with Novartis and, more dramatically, Merck KGaA acquiring Bio-Techne for $11.3B signal that enabling technologies are now priced as strategic infrastructure, not speculative optionality. When a tools company commands a TDV north of $11B, the market is saying these assets are as mission-critical as a Phase III oncology program.

Second, pipeline math is forcing diversification. The top 20 pharma companies face a combined $250B+ in revenue exposure from patent cliffs through 2030 (per Evaluate Pharma's 2026 consensus forecasts). Traditional in-licensing of late-stage clinical assets in oncology, immunology, and CNS remains brutally competitive — median upfront payments for Phase II oncology assets crossed $150M in early 2026 according to Deal Benchmarks tracked on this platform. Acquirers are rationally pivoting to platform deals that generate multiple pipeline candidates across TAs, amortizing the upfront over a broader set of shots on goal.

Third, China-origin deals are accelerating into the "other" bucket. YaoPharma's $2.05B TDV deal with Pfizer — $150M upfront — exemplifies a growing class of transactions where Chinese biotechs are out-licensing assets or capabilities that span manufacturing, formulation, or multi-TA platforms rather than single-indication molecules. These deals don't fit neatly into oncology or cardiovascular buckets, so they land in "other." That classification masks their strategic significance: Pfizer didn't pay $150M upfront for a filing cabinet. It paid for optionality across therapeutic areas.

Notable Deals

The Bio-Techne/Merck KGaA transaction dominates this dataset and deserves scrutiny. At $11.3B, this is the largest tools-and-reagents acquisition in biopharma history. Bio-Techne's portfolio — spanning recombinant proteins, antibodies, and advanced cell analysis instruments — gives Merck KGaA vertical integration across its life science division. This is not a traditional licensing deal; it's a supply-chain acquisition dressed in biopharma clothing. The multiple data entries (June 15 and June 25–28) likely reflect amendment or staged closing disclosures, but the economic signal is singular: Merck KGaA valued enabling infrastructure at a premium that exceeds what most acquirers pay for Phase III-ready clinical programs.

Generate: Biomedicines' partnership with Novartis, while lacking disclosed financial terms, carries different strategic weight. Novartis has been systematically building an AI-native drug design capability, and Generate's generative biology platform represents a bet on computationally designed proteins and therapeutics. The absence of disclosed deal terms is itself informative — it suggests either a tight equity-linked structure or an option-based framework that doesn't map to conventional upfront/milestone disclosure. BD teams evaluating AI-biology platform partnerships should monitor this deal for structural precedent.

YaoPharma/Pfizer at $150M upfront and $2.05B TDV is the deal that should concern every mid-stage biotech negotiating with Big Pharma. A $150M upfront for a Chinese-origin platform asset with $2B in biobucks signals that upfront-to-TDV ratios in platform deals are compressing — buyers are paying roughly 7% upfront, loading economics into milestones. Compare that to the 15–25% upfront ratios typical in indication-specific Phase II licensing. If you're a seller with a platform asset, negotiate harder on the upfront or accept that your payout depends on milestone execution.

What This Means for BD Teams Right Now

If you're selling a platform or enabling-technology asset, this is your market. The window is open. Twenty-seven deals in six months after a dead-zero period means buyers have budget authorization and board-level conviction. But don't confuse volume with generosity. The YaoPharma/Pfizer deal structure — heavy on milestones, light on upfront relative to TDV — suggests buyers are using competitive dynamics to cap upfront exposure. Run your deal economics through Solidus before entering term sheet negotiations; the gap between headline TDV and risk-adjusted NPV in platform deals is wider than in traditional licensing.

If you're buying, move now but structure defensively. The Bio-Techne acquisition will create a reference-price anchor that inflates valuation expectations across the tools/platform sector for the next 12–18 months. Every mid-cap tools company with $500M in revenue will point to the Bio-Techne multiple. Smart acquirers will use option-based deal structures — rights of first negotiation, equity stakes with call options, co-development frameworks — to lock in access without paying acquisition premiums driven by a single outlier transaction.

Deal structures gaining favor: Platform licensing with multi-TA milestone stacks. Equity-linked partnerships where the buyer takes a stake and attaches co-development rights. Option-to-acquire structures that let the buyer validate the platform on one TA before committing to a full buyout. Structures losing favor: Single-indication exclusive licenses for platform assets. Flat-fee technology access agreements without upside sharing. If your term sheet looks like a 2019 licensing deal, you're leaving value on the table — check current benchmarks at Deal Benchmarks.

Benchmark your deal against current market rates. Whether you're structuring a platform out-license or evaluating an acquisition target in the enabling-tech space, the 2026 other-deal data set is your comp table. Use the Ambrosia calculator to stress-test upfront/milestone splits, probability-weight your TDV, and see how your proposed terms stack against the 27 deals that reshaped this category in six months.